Successful Treatment of Cosmetic Eyebrow Tattoos in Fitzpatrick III-IV With Picosecond (1,064, 532-nm) Neodymium-Doped Yttrium Aluminum Garnet Laser With a Perfluorodecalin-Infused Patch: A Pilot Study.

Background And Objectives: Nanosecond Q-switched lasers have been used for the removal of traditional and cosmetic tattoos. Picosecond lasers utilize pulse durations of 10 and provide more efficient clearance of tattoos. Safe and effective removal of tattoos is especially important in cosmetically sensitive areas such as the face.

Melasma: update on management.

Melasma is a common, acquired, chronic cutaneous pigment disorder that is often difficult to treat and has a high recurrence rate. The goal of a melasma treatment regimen is to decrease pigment production and increase elimination. Topical tyrosinase inhibitors block melanin synthesis and thereby reduce pigment production.

Perfluorodecalin-infused patch in picosecond and Q-switched laser-assisted tattoo removal: Safety in Fitzpatrick IV-VI skin types.

Background: The topical transparent perfluorodecalin-infused (PFD) silicone patch has been demonstrated to reduce epidermal whitening produced in association with laser-assisted tattoo removal. This optical clearing agent has enabled multiple laser passes to be made in one treatment session. Previous studies using the PFD patch have showed enhanced clearance with picosecond and Q-Switched lasers on blue/black tattoos in Fitzpatrick skin types I-III.

Accelerated tattoo removal with acoustic shock wave therapy in conjunction with a picosecond laser.

Background: Conventional tattoo removal consists of single-pass treatments, spaced 7-8 weeks apart, for a total of 7-10 sessions. A major limiting factor of this procedure is the development of cavitation bubbles and vacuoles within the epidermis and dermis that result from the rapid heating of tattoo particles by the laser. While multiple-pass methods using the R20 protocol or the PFD patch enhance tattoo removal through epidermal clearance, they have no effect on deep-intradermal pigment associated vacuoles that arise from treatment with lasers such as the Q-switched laser.

One-year follow-up of a TRASER clinical trial for the treatment of nasal telangiectasias.

Objectives: To evaluate the long-term efficacy of treating nasal telangiectasias with the TRASER device.

Methods: Subjects from the TRASER efficacy analysis clinical trial were invited for a 1-year follow-up. Standardized photographs were taken to compare to baseline.